Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New graft promises better healing after skin cancer removal

NCT ID NCT06919809

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a special skin graft called X A-DERM™ mADM in 16 people who had Mohs surgery to remove skin cancers like basal cell carcinoma or squamous cell carcinoma. The graft has a micro-textured surface designed to help the wound heal faster and leave a better scar. Researchers checked healing with photos and scar assessments over 60 days. The goal was to see if this graft improves recovery compared to standard methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
X A-DERM™ microsurfaced acellular dermal matrix (mADM) graft
What this could lead to
If it works, this could provide a better way to heal wounds and reduce scarring after skin cancer removal surgery.
What could go wrong
This is a very small, single-arm study with only 16 participants, so results may not apply to everyone. The device is new and may not improve healing over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

16 people

The number who actually took part.

Started

Aug 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects must meet all the following criteria to be entered into the study: 1. Between 18 and 85 years of age, inclusive 2. Subject in good health, or with stable treated medical condition, as determined by the investigator. 3. Scheduled to undergo elective Mohs surgery to remove a single biopsy-proven basal cell carcinoma (BCC), squamous cell carcinoma (SCC), or melanoma in situ (MIS) lesion on the head, face, or upper extremity that is amenable to Mohs surgery. 4. Tumor location and size meets the following criteria for immediate MMS: * Largest total surface area of ≤16cm2 and smallest total surface area per PI discretion. * Depth with majority of tumor excision at least to subcutaneous tissue. * Adequate dermal contract with graft. 5. Willing and able to complete and comply with procedures, protocol requirements, and instructions, including self-performed wound care and completion of all required visits. 6. Able to speak, read, write, and understand the language of the informed consent form (ICF) and study questionnaires. 7. Willingness and ability to understand the risks, benefits, and alternatives to participation, and give informed consent. \- Exclusion Criteria: Subjects who meet the above inclusion criteria will be eligible for the study, unless they present with any of the following: 1. History of wound abnormalities or any other findings that would impede participation in the trial, as per PI discretion. 2. Post-operative defects superficial and deemed not appropriate for second intention healing, as determined by the investigator. 3. Pregnant, lactating/breast feeding, or planning a pregnancy. A negative urine pregnancy test will be required at screening for female subjects of childbearing potential; a woman will be considered to be of childbearing potential unless she has had a tubal ligation, total hysterectomy, bilateral oophorectomy, or is postmenopausal (without a menstrual period for at least one year). \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCC - basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bare Dermatology

    Rockwall, Texas, 75032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.